Reference health
Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives
43/43 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
36 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 43 checked references that resolve
resolves10.1080/01932699808913170
THE FUNCTION OF GELATIN IN CONTROLLED PRECIPITATION PROCESSES OF NANOSIZE PARTICLES
resolves10.1002/elps.11501401214
Colloidal carriers for intravenous drug targeting: Plasma protein adsorption patterns on surface‐modified latex particles evaluated by two‐dimensional polyacrylamide gel electrophoresis
resolves10.1159/000065608
Enhanced Ocular Anti-Inflammatory Activity of Ibuprofen Carried by an Eudragit RS100<sup>®</sup> Nanoparticle Suspension
resolves10.1002/jps.21714
Pharmacokinetic and Pharmacodynamic Evaluation of the Suitability of Using Fluticasone and an Acute Rat Lung Inflammation Model to Differentiate Lung Versus Systemic Efficacy
resolves10.1016/j.jconrel.2006.11.011
Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals
resolves10.1016/j.jconrel.2008.03.002
A novel bottom–up process to produce drug nanocrystals: Controlled crystallization during freeze-drying
resolves10.1016/j.ejps.2009.07.005
Preparation of drug nanocrystals by controlled crystallization: Application of a 3-way nozzle to prevent premature crystallization for large scale production
resolves10.1016/j.ijpharm.2010.02.013
Understanding the structure and stability of paclitaxel nanocrystals
resolves10.1016/S0939-6411(03)00043-2
Characterization of solidified reverse micellar solutions (SRMS) and production development of SRMS-based nanosuspensions
resolves10.1016/j.ijpharm.2008.09.022
Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery
resolves10.1007/s11051-008-9357-4
Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system
resolves10.1016/j.ijpharm.2007.12.016
Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions
resolves10.1111/j.1742-7843.2008.00213.x
Oral Delivery of 1,3‐Dicyclohexylurea Nanosuspension Enhances Exposure and Lowers Blood Pressure in Hypertensive Rats
resolves10.1080/10611860500353245
Characterization of nebulized buparvaquone nanosuspensions—effect of nebulization technology
resolves10.1093/toxsci/kfi293
Research Strategies for Safety Evaluation of Nanomaterials, Part II: Toxicological and Safety Evaluation of Nanomaterials, Current Challenges and Data Needs
resolves10.1016/S1548-5315(11)70224-8
Cremophor EL-containing paclitaxel-induced anaphylaxis: a call to action
resolves10.1016/j.ijpharm.2007.03.011
Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs
resolves10.1016/S0378-5173(00)00640-2
A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications
resolves10.1016/S0378-5173(02)00686-5
Formulation of amphotericin B as nanosuspension for oral administration
resolves10.1016/j.ejpb.2005.05.009
Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation
resolves10.3109/10601339609035953
Cosmetic Regulations of the United States, European Union, and Japan
resolves10.1016/S0169-409X(96)00474-7
Amphotericin B encapsulated in polyethylene glycol-immunoliposomes for infectious diseases
resolves10.1016/S0168-3659(97)00061-8
Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood–brain barrier using surfactant-coated nanoparticles
resolves10.1016/0378-5173(95)00122-Y
Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs
resolves10.1016/S0928-0987(02)00251-8
Nanosizing: a formulation approach for poorly-water-soluble compounds
resolves10.1016/j.ejpb.2005.09.005
Spray coated pellets as carrier system for mucoadhesive drug nanocrystals
resolves10.1016/S0378-5173(02)00040-6
Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability
resolves10.1093/jac/45.1.77
Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection
resolves10.1007/s11095-007-9445-7
A Novel Solid-in-oil Nanosuspension for Transdermal Delivery of Diclofenac Sodium
resolves10.1016/j.ijpharm.2007.02.030
Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat
resolves10.1128/AAC.45.6.1771-1779.2001
Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis
resolves10.1016/j.nano.2010.10.012
In vitro protein adsorption studies on nevirapine nanosuspensions for HIV/AIDS chemotherapy
resolves10.1007/s11671-007-9063-7
Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment
resolves10.1016/S1076-6332(99)80062-2
Lymph node extraction of radiopaque nanoparticulates in the rabbit as measured in vivo with CT
resolves10.1211/jpp.60.9.0006
Distribution of an intravenous injectable nimodipine nanosuspension in mice
The 36 references without a DOI — listed, not checked
no DOI — not checkedAl Shaal, L., Shegokar, R., Müller, R.H., 2010a. Apigenin smartCrystals for novel UV skin protection formulations. Eighth European Workshop on Particulate Systems Abstract no. 22.
no DOI — not checkedAl Shaal, L., Shegokar, R., Müller, R.H., Keck, C.M., 2010b. Novel UV skin protective antioxidant nanocrystals. First Combined Annual Meeting of the International Pharmaceutical Federation, PSWC and AAPS. Abstract No. 2221.
no DOI — not checkedAuweter, H., Bohn, H., Heger, R., Horn, D., Siegel, B., Siemensmeyer, K., 2002. Precipitated water-insoluble colorants in colloid disperse form, in US Patent 6,494,924. BASF AG.
no DOI — not checkedBöhm, B.H.L., 1999. Herstellung und Charakterisierung von Nanosuspensionen als neue Arzneiform für Arzneistoffe mit geringer Bioverfügbarkeit. Ph.D. Thesis, Freie Universität Berlin, Germany.
no DOI — not checkedChow, D.S.L., Gupta, P., Qi, Y., Liang, D., Shah, J., Wisniecki, P., 2010. Parenteral and Oral Formulations of Benzimidazoles. WO/2010/011289.
no DOI — not checkedPolymeric ocular nanosuspension for controlled release of acyclovir: in vitro release and ocular distribution
no DOI — not checkedLiposome in Kosmetika und Arzneimitteln
no DOI — not checkedHaynes, D.H., 1992. Phospholipid-coated microcrystals: injectable formulations of water insoluble drugs. US Patent 5091187.
no DOI — not checkedHernandez-Trejo, N., 2006. Development and characterisation of buparvaquone nanosuspensions for pulmonary delivery in the treatment of Pneumocystis pneumonia. Ph.D. Thesis, Freie Universität Berlin, Germany.
no DOI — not checkedSecond generation of drug nanocrystals for delivery of poorly soluble drugs: smartCrystal technology
no DOI — not checkedKipp, J.E.W., Joseph, C.T., Doty, M.J., Rebbeck, C.L., 2001. Microprecipitation method for preparing submicron suspensions. US Patent 6869617.
no DOI — not checkedList, M., Sucker, H., 1988. Pharmaceutical colloidal hydrosols for injection. GB Patent 2200048.
no DOI — not checkedLiversidge, G.G., Cundy, K.C., Bishop, J., Czekai, D., 1992. Surface modified drug nanoparticles. US Patent 5145684.
no DOI — not checkedLück M., 1997. Plasmaproteinadsorption als ein möglicher Schlüsselfaktor für eine kontrollierte Arzneistoffappliktion mit partikulären Trägern. Ph.D. Thesis, Freie Universität Berlin.
no DOI — not checkedMauludin, R., 2008. Nanosuspensions of poorly soluble drugs for oral administration. Ph.D. Thesis, Freie Universität Berlin, Germany.
no DOI — not checkedDrug nanocrystals of poorly soluble drugs
no DOI — not checkedMüller, R.H., Becker, R., Kruss, K.P., 1992. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. US Patent 5858410.
no DOI — not checkedMüller, R.H., Becker, R., Kruss, B., Peters, K., 1999. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. US Patent 5858410.
no DOI — not checkedNanosuspensions—a formulation approach for poorly soluble and poorly bioavailable drugs
no DOI — not checkedMüller, R.H., Krause, K., Mäder, K., 2001b. Method for controlled production of ultrafine microparticles and nanoparticles. WO/2001/003670.
no DOI — not checkedMüller, R.H., Pardeike, J., Hommoss, A., 2006. Nanoparticles in therapeutics: drug nanocrystals and lipid nanoparticles. NanoTrends, Potsdam, Germany.
no DOI — not checkedMüller, R.H., Shegokar, R., Singh, K.K., 2009. Positively charged nanostructured lipid carriers (NLC) for drug delivery by adhesion. Ninth International Symposium on ‘Advances in Technology and Business Potential of New Drug Delivery Systems’ Controlled Release Society-Indian Local Chapter,Mumbai, India, P36.
no DOI — not checkedItraconazole nanosuspension meant for oral use: development of formulation, characterization and in vitro comparison with some marketed formulations
no DOI — not checkedPetersen, R., 2006. Nanocrystals for use in topical cosmetic formulations and method of production thereof. US Patent 60/8866233.
no DOI — not checkedPharmacokinetics of drugs administered in nanosuspension
no DOI — not checkedIn vivo pharmacokinetic studies of albendazole nanoparticulate oral formulations for improved bioavailability
no DOI — not checkedShegokar, R., 2010. Development and evaluation of novel drug delivery systems for an anti-HIV Drugs. Ph.D. Thesis, S.N.D.T. Women's University, Mumbai, India.
no DOI — not checkedShegokar, R., Singh, K.K., 2009. Antiretroviral Nanosuspensions for Latent HIV Reservoir Targeting. 36th Annual Meeting and Exposition of the Controlled Release Society, Copenhagen, Denmark., Abstract No. 588.
no DOI — not checkedShegokar R., Singh K.K., Müller R.H., 2009. Targeting to Latent HIV reservoirs: production optimization and evaluation of nevirapine nanosuspensions, 69th International Congress of FIP. Istanbul, Turkey. Abstract No. 451.
no DOI — not checkedShegokar, R., Al Shaal, L., Müller, R.H., Keck, C.M., 2010a. Apeginin nanocrystal for supportive anticancer treatment. Int. J. Pharm., submitted for publication.
no DOI — not checkedShegokar, R., Al Shaal, L., Müller, R.H., 2010b. Local anaesthetic nanocrystal as prologed release formulation. First Combined Annual Meeting of the International Pharmaceutical Federation, PSWC and AAPS New Orleans, Louisiana, USA, Abstract no. 2203.
no DOI — not checkedSuker, H., Gassmann, P., 1994. Improvements in pharmaceutical compositions. GB Patent 2269536A.
no DOI — not checkedUS-FDA. http://www.fda.gov/Food/FoodIngredientsPackaging/GenerallyRecognizedasSafeGRAS/default.htm.
no DOI — not checkedweblink1, http://www.wissenschaft-technik-ethik.de/wasser_dampfdruck.html.
no DOI — not checkedweblink2, www.caelo.de/getfile.html?type=sdb&num=3274.
no DOI — not checkedweblink3, http://www.europarl.europa.eu/sides/getDoc.do?type=IM-PRESS&reference=20090323IPR52331&language=EN.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/j.ijpharm.2010.07.044"><img src="https://citestamp.com/citestamped/10.1016/j.ijpharm.2010.07.044/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1016/j.ijpharm.2010.07.044)